Phase II trial of anguidine in patients with sarcomas unresponsive to prior chemotherapy: A Southwest Oncology Group Study.
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology; D004341:Drug Evaluation; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D011379:Prognosis; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology; D012717:Sesquiterpenes / Q000627:therapeutic use*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000473:pathology; D013921:Thrombocytopenia / Q000139:chemically induced; D014255:Trichothecenes / Q000009:adverse effects / Q000627:therapeutic use*
D012717:Sesquiterpenes; D014255:Trichothecenes; C001809:diacetoxyscirpenol